What to know as first FDA-approved GLP-1 pill for weight loss heads for pharmacies
The FDA has approved the first GLP-1 pill for weight loss and it’s expected in pharmacies in the coming weeks. Dr. Holly Lofton, director of the Medical Weight Management Program at NYU Langone, joins CBS News to discuss. CBS News 24/7 is the premier anchored streaming news service from CBS News and Stations that is […]
6 new care and payment models CMS introduced in 2025
CMS introduced several new care and payment models in 2025, many focused on drug pricing, chronic disease management and prevention: 1. CMS published plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. Under the model, CMS will negotiate reduced prices with GLP-1 manufacturers for […]
Can Amgen’s MariTide Take on Leaders in the Obesity Space?
Amgen AMGN is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor agonist, as part of its comprehensive MARITIME phase III program in obesity. With this drug, Amgen intends to take on Eli Lilly LLY and Novo Nordisk NVO, which currently dominate […]
Obesity efforts dominate dealmaking in 2025
When glucagon-like peptide-1 (GLP-1) receptor agonists entered the market for obesity and overweight indications in recent years, the uptake and enthusiasm drove investor excitement for companies advancing any of the new mechanisms in the space.
Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according to a study published in the Dec. 18/25 issue of the New England Journal of Medicine.
The weight-loss drugs on trial in 2026 may trump Ozempic and Zepbound
Drugs like Ozempic, Wegovy and Zepbound have transformed how we treat obesity, but more effective treatments could be down the road
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses
Quick Read Hims scaled to $2.2B in revenue and 2.7M subscribers but margins fell from 6.5% to 2% as infrastructure spending surged. Subscriber growth slowed from 700K in 2024 to 480K in 2025 after FDA removed semaglutide from shortage list. A $1,000 investment at public debut returned 173.5% over five years despite recent pullback from […]
Novo Nordisk just pulled off something nobody saw coming – Yahoo Finance
Novo Nordisk just pulled off something nobody saw coming Yahoo Finance Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient CNBC FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults PR Newswire Weight-Loss Drugs Are Changing. Here’s What to Know Bloomberg.com With the […]
Semaglutide Tied to Fewer Hospitalizations in Heart Patients
Semaglutide use is linked to fewer hospitalizations and fewer days in the hospital for patients with cardiovascular disease and overweight or obesity, signaling benefits beyond cardiovascular events. Medscape Medical News
The Year That Shattered American Science
For all of the political chaos that American science endured in 2025, aspects of this country’s research enterprise made it through somewhat … okay. The Trump administration terminated billions of dollars in research grants; judges intervened to help reinstate thousands of those contracts. The administration threatened to cut funding to a number of universities; several […]